32 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33623141 | FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. | 2021 May | 5 |
2 | 33846544 | Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. | 2021 May | 1 |
3 | 31919472 | FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. | 2020 Mar | 1 |
4 | 32441887 | Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. | 2020 Jul | 6 |
5 | 30681373 | Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. | 2019 Mar | 1 |
6 | 31528345 | Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. | 2019 | 1 |
7 | 31648336 | Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. | 2019 Oct 22 | 1 |
8 | 30514344 | FLT3 inhibitors in acute myeloid leukemia. | 2018 Dec 4 | 1 |
9 | 27872058 | A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. | 2017 Mar 2 | 4 |
10 | 27450971 | FLT3 Inhibitors for Treating Acute Myeloid Leukemia. | 2016 Oct | 1 |
11 | 26547689 | Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. | 2015 Nov 7 | 7 |
12 | 26625890 | Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. | 2015 Dec | 1 |
13 | 24883179 | The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. | 2014 Jun | 2 |
14 | 23294096 | MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. | 2013 Mar | 1 |
15 | 21263155 | FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. | 2011 Mar 24 | 2 |
16 | 21270442 | Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. | 2011 Mar 24 | 3 |
17 | 20141349 | Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. | 2010 Mar | 2 |
18 | 21082990 | Lestaurtinib: a multi-targeted FLT3 inhibitor. | 2009 Feb | 2 |
19 | 18217204 | A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. | 2008 Jun | 1 |
20 | 18271064 | Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. | 2008 Jun | 1 |
21 | 18341639 | Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. | 2008 May | 2 |
22 | 17359372 | FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. | 2007 Apr | 2 |
23 | 17442779 | Effect of FLT3 inhibition on normal hematopoietic progenitor cells. | 2007 Jun | 2 |
24 | 16761017 | Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. | 2006 Aug | 2 |
25 | 16857985 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. | 2006 Nov 15 | 4 |
26 | 16868253 | The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. | 2006 Nov 15 | 2 |
27 | 15374878 | FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. | 2005 Jan 15 | 4 |
28 | 15574429 | FLT3/ITD mutation signaling includes suppression of SHP-1. | 2005 Feb 18 | 1 |
29 | 16105978 | Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. | 2005 Dec 1 | 2 |
30 | 14726387 | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. | 2004 May 15 | 2 |
31 | 15126317 | In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. | 2004 Aug 15 | 2 |
32 | 12010785 | A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. | 2002 Jun 1 | 2 |